Insulin Pump Cybersecurity Patents: Who Leads, White Space 2026
- Filings are accelerating again after dropping to zero at the 2022 midpoint, following a 2020 peak of 6 annual filings.
- Claim activity is lopsided G16H and A61M cover the large majority of the 53 families, while the wireless (H04W) and recognition (G06K) layers carry only a handful of records each.
- One architecture anchors the field a single secure-pairing patent and its continuation account for the two highest citation counts in the dataset.
A young field built on one dominant pairing architecture
Insulin pump cybersecurity sits at the intersection of drug-delivery hardware and network security: claims here combine A61M5/172 insulin-delivery mechanics with H04L9 cryptographic methods and G16H40 healthcare device-management informatics. The 53 families in this corpus span filings from 2017 through a partial 2026, concentrated overwhelmingly through the US receiving office. Two claim clusters carry most of the citation weight: secure device-pairing architectures, and integrated delivery systems that authenticate continuous glucose sensor data before it drives a dosing decision.
Filing activity dipped to zero at the 2022 midpoint after a 2020 peak, then resumed an upward trend — publication lag of roughly 18 months means the 2025–2026 totals shown here are undercounts of the true current filing rate. Technology composition is lopsided: G16H and A61M subclasses carry the bulk of records, while the wireless-network and pattern-recognition subclasses remain comparatively thin.
How filing activity and technology focus have shifted since 2017
The filing trend and IPC composition below show where insulin pump cybersecurity claims are concentrated today, and where activity is still building.
Filings accelerating off a mid-decade dip
Annual filings rose from 3 in 2017 to a peak of 6 in 2020, dropped to 0 at the 2022 midpoint, and the trend since has been climbing again — 2026 figures are partial because of publication lag, so the true current-year total is understated.
Healthcare informatics and delivery hardware dominate
G16H (healthcare informatics) and A61M (body-fluid delivery devices) cover the large majority of records, while H04L, H04W and G06K — the network-security and pattern-recognition subclasses — together account for a small fraction, marking them as comparatively open ground.
Shares are the percentage of the 53 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Insulin Pump Cybersecurity with Eureka
This page is one run against one query. Ask Eureka your own question about insulin pump cybersecurity and every answer comes back with the patent numbers behind it.
Try EurekaThe claims setting the boundaries of this field
Secure communication architecture for medical devices
A computer-implemented method establishes a secure wireless connection between an insulin pump device and a mobile computing device: the mobile device receives a device identifier for the pump, retrieves device information from a remote server using that identifier, establishes a secure wireless connection using the device information, and authenticates the pump using asymmetric key verification against a public key.Abstract text drawn directly from the granted patent record.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US9980140B1 | Secure communication architecture for medical devices | 564 |
| 2 | US20140039383A1 | Integrated insulin delivery system with continuous glucose sensor | 204 |
| 3 | US10341866B1 | Secure communication architecture for medical devices | 101 |
| 4 | US9452258B2 | Integrated insulin delivery system with continuous glucose sensor | 61 |
| 5 | US20140128803A1 | Integrated insulin delivery system with continuous glucose sensor | 50 |
| 6 | US8687811B2 | Diabetes care kit that is preconfigured to establish a secure bidirectional communication link between a bloo… | 45 |
| 7 | US9452259B2 | Integrated insulin delivery system with continuous glucose sensor | 43 |
| 8 | US9457146B2 | Integrated insulin delivery system with continuous glucose sensor | 41 |
| 9 | US20120093311A1 | Efficient procedure for pairing medical devices for wireless communication with limited user interaction | 41 |
| 10 | US9463277B2 | Integrated insulin delivery system with continuous glucose sensor | 40 |
Ranked by citation count within the searched corpus; older filings are structurally favoured over recent ones.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the citation and filing data actually shows
These figures come directly from the 53-family corpus behind this page — they describe where claim density and influence currently sit, not where the technology is headed next.
One pairing architecture dominates influence
US9980140B1 and its continuation US10341866B1 together account for the two highest citation counts in the set, both built around server-mediated asymmetric-key device authentication.
Filing is heavily US-centric
Forty of the 53 records were filed through the US receiving office, with Europe, India, Denmark and the PCT route covering the remainder in much smaller numbers.
The radio layer is comparatively unclaimed
Against 51 records in G16H and 44 in A61M, only 3 touch H04W wireless-network claims and 2 touch G06K recognition — the network and detection layers sit well behind the device-and-data-management layer.
Growth dipped, then resumed
Filings ran from 3 in 2017 to a 2020 peak of 6, fell to 0 at the 2022 midpoint, and the trend since is climbing again, though the 2026 figure is partial.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to insulin pump cybersecurity, with the prior art for and against each one.
Who is filing, and where the activity has stalled
The assignee set spans device makers, diagnostics firms and individual inventors, with several named assignees showing no filings in the most recent tracked year — a pattern that may reflect a genuine pause or simply publication lag.
Several leading filers show zero recent activity
Dexcom, Inc., Roche Diagnostics Operations, Inc., F. Hoffmann-La Roche AG, Roche Diagnostics GmbH and Bigfoot Biomedical, Inc. all show zero filings in the latest tracked year, with Dexcom, Inc. down -100% YoY.
Joint filing is limited but present
Ten co-assignee pairs appear in the dataset, the strongest between F. Hoffmann-La Roche AG and Roche Diagnostics GmbH, alongside repeated inventor pairings such as MAHALINGAM AARTHI with KAMATH APURV ULLAS and with DOBBLES MIKE.
A moderate field, not yet a crowded one
With 53 total families across the full search window, this is a smaller landscape than mainstream device categories — room remains for new entrants to establish claim positions, particularly outside the dominant pairing-architecture cluster.
| Assignee | Recent year | YoY |
|---|---|---|
| Dexcom, Inc. | 0 | -100% |
| Roche Diagnostics Operations, Inc. | 0 | — |
| F. Hoffmann-La Roche AG | 0 | — |
| Roche Diagnostics GmbH | 0 | — |
| Bigfoot Biomedical, Inc. | 0 | — |
| MAHALINGAM AARTHI | 0 | — |
| KAMATH APURV ULLAS | 0 | — |
| DOBBLES MIKE | 0 | — |
Where to take this analysis
The filing and citation patterns above point to specific next steps depending on whether you are clearing a design or scouting a filing position.
Run a freedom-to-operate check against the pairing cluster
If your architecture uses server-mediated device-identifier lookup followed by asymmetric-key authentication, compare it directly against US9980140B1 and its continuation before finalising a design.
Open Eureka to compare claimsScope a filing in the under-claimed wireless layer
H04W and G06K coverage is thin relative to the G16H and A61M core — a well-drafted wireless re-authentication or sensor-recognition claim may face less prior art than a pairing-architecture filing today.
Draft a claim scope in EurekaInsulin pump cybersecurity patents: what practitioners ask
The most-cited record in this dataset is US9980140B1, a secure communication architecture for medical devices credited to Insulet Corporation, followed closely by its own continuation US10341866B1. A separate but heavily cited cluster covers integrated insulin-delivery systems paired with continuous glucose sensors. Citation count favours older filings, so treat this as a map of influence within the searched corpus rather than a claim that these are the newest or most commercially dominant patents today.
This landscape is defined by the intersection of A61M5/172 (insulin delivery devices), H04L9 (cryptographic techniques for digital transmission) and G16H40 (healthcare informatics for device management). In practice, G16H and A61M carry the bulk of the 53 records, while H04L, H04W and G06K — the network and pattern-recognition layers — are comparatively thin. That split tells you claim activity has focused more on the device-and-data-management layer than on the radio or recognition layers.
Filings rose from 3 in 2017 to a peak of 6 in 2020, dipped to 0 at the 2022 midpoint, and the underlying trend since has turned upward again. Because publication typically lags filing by around 18 months, the most recent year in any dataset like this one is always undercounted, so the actual 2025–2026 filing rate is likely higher than currently visible. Read the recent uptick as accelerating interest rather than a plateau.
The thinnest IPC subclasses in this corpus are H04W (wireless communication networks) and G06K (data recognition), each with only a handful of records against 51 in G16H and 44 in A61M. That gap suggests wireless-link hardening after initial pairing, and pattern-recognition-based tamper or spoofing detection tied to dosing decisions, are both under-claimed relative to the device-pairing and delivery-system claims that dominate today. A first filer in either branch would face less prior art than in the pairing-architecture core.
Filing activity in this space includes device manufacturers and diagnostics firms, with several assignees showing zero filings in the most recent tracked year — a pattern consistent with either a pause in filing or simply publication lag masking newer applications. Co-assignee pairs in the dataset, such as the pairing between F. Hoffmann-La Roche AG and Roche Diagnostics GmbH, point to some joint filing activity between related corporate entities. The ranking table on this page reflects the full 53-family set rather than a hand-picked shortlist.
Research Insulin Pump Cybersecurity in depth with Eureka
Go past this page: query the whole insulin pump cybersecurity corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.